✦ LIBER ✦

7053 POSTER Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer

✍ Scribed by Reuter, C.; Morgan, M.; Fenner, M.; Ivanyi, P.; Grünwald, V.; Ganser, A.

Book ID: 123086707
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 44 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)72004-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Carboplatin plus weekly docetaxel as sal

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

✍ Christoph W. M. Reuter; Michael A. Morgan; Philipp Ivanyi; Martin Fenner; Arnold 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 359 KB

Estramustine plus docetaxel as second-li

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone

✍ Orazio Caffo; Teodoro Sava; Evi Comploj; Maria Anna Giampaolo; Romana Segati; Fr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 145 KB

761 PREDICTION OF LEUKOPENIA AFTER DOCET

761 PREDICTION OF LEUKOPENIA AFTER DOCETAXEL CHEMOTHERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

✍ Nakashima, Jun; Takizawa, Issei; Ko, Kazuyoshi; Nakagami, Yoshihiro; Ohori, Mako 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 96 KB

Response to docetaxel/carboplatin-based

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

✍ Mari Nakabayashi; Oliver Sartor; Susanna Jacobus; Meredith M. Regan; David McKea 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Clinical outcome of patients with doceta

Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy

✍ Thomas Nelius; Tobias Klatte; Werner de Riese; Allan Haynes; Stephanie Filleur 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 201 KB

223 VERSICAN IS A PROMISING CANDIDATE BI

223 VERSICAN IS A PROMISING CANDIDATE BIOMARKER IN THE COMBINATION OF DOCETAXEL WITH THALIDOMIDE AS SECOND LINE CHEMOTHERAPY IN CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL RESISTANCE

✍ Shiina, Hiroaki; Yasumoto, Hiroaki; Hiraki, Miho; Arichi, Naoko; Mitsui, Yozo; H 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 62 KB